Dyne Therapeutics, Inc. DYN
18.04 USD +0.12 (+0.67%)
Nov 11, 2026, 9:37 AM EST
17.90 Day range 18.12
14.00 52-week range 27.31
- YTD
- -7.77%
- 1 year
- -8.29%
News
globenewswire.com Dyne Therapeutics to Participate in Upcoming Investor Conference WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
benzinga.com PepGen Stock Doubles in One Session - Here's Why PepGen reports positive Phase 2 results for PGN-EDODM1 in DM1, showing record splicing correction and notable functional improvements.
benzinga.com Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.92) by 15.22 percent. This is a 39.47 percent decrease over losses of…
globenewswire.com Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -
benzinga.com Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, while Amdocs plunged 39% after missing Q4 estimates and issuing weak FY27 guidance; several other stocks also fell premarket.
benzinga.com Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Limbach surged 14.7% after beating Q3 estimates and raising FY26 sales guidance; Curis gained 69.5%, while Cenntro plunged 46.5%.
benzinga.com Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15 Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
benzinga.com HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32 HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.- benzinga.com Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a…
benzinga.com Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.
benzinga.com Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36 Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.- benzinga.com RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30 RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.
benzinga.com Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26 Baird analyst Brian Skorney maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $30 to $26.
benzinga.com Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
benzinga.com Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
benzinga.com Dyne Therapeutics To Demonstrate Additional One-Year Results From Phase 1/2 ACHIEVE Study Of Zeleciment Basivarsen For DM1 At Annual International Congress Of World Muscle Society Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it…
benzinga.com Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.- benzinga.com Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45 Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
benzinga.com RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35 RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $30 to $35.- benzinga.com Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.75) by 44 percent. This is a 11.34 percent decrease over losses of…
benzinga.com Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.
benzinga.com Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
benzinga.com Dyne Therapeutics Stock Tumbles After Hours: Here's Why Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals…
- benzinga.com Dyne Therapeutics' Biologics License Application For Zeleciment Rostudirsen Got FDA Acceptance For Review To Treat Duchenne Muscular Dystrophy Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the…
- benzinga.com Dyne Therapeutics Completes Enrollment In Registrational Expansion Cohort Of Phase 1/2 ACHIEVE Trial Of Zeleciment Basivarsen In Individuals With DM1 - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage…
- benzinga.com Dyne Therapeutics Submits Biologics License Application To FDA For Zeleciment Rostudirsen To Duchenne Muscular Dystrophy Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the…
benzinga.com Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping - 72-week trial will enroll approximately 90 participants; first site now open for enrollment -- Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle…- benzinga.com Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33 Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $34 to $33.
- benzinga.com Bernstein Maintains Market Perform on Dyne Therapeutics, Raises Price Target to $24 Bernstein analyst William Pickering maintains Dyne Therapeutics (NASDAQ:DYN) with a Market Perform and raises the price target from $23 to $24.
- benzinga.com Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 30.48 percent increase over losses of…
benzinga.com Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial results and Capricor Therapeutics announced a new PDUFA date for Deramiocel BLA.- benzinga.com Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $38 Price Target Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $38 price target.
benzinga.com Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.- benzinga.com On Sunday, Dyne Therapeutics Said It Initiated Phase 3 HARMONIA Trial Of Zeleciment Basivarsen (Z-basivarsen, DYNE-101) For Myotonic Dystrophy Type 1 HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1.48-week trial will enroll approximately 150 individuals, and first sites are now open for…
- benzinga.com On Sunday, Dyne Therapeutics Shared Additional Data From The Ongoing Phase 1/2 DELIVER Trial Of Zeleciment Rostudirsen (Z-rostudirsen, DYNE-251) For Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping Dyne announced the results of new analyses of cardiac and pulmonary function amongst all DELIVER participants who were randomized to z-rostudirsen treatment at baseline (any dose1) and for whom…
- benzinga.com Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $47 Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $50 to $47.
- benzinga.com HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $50 HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $60 to $50.
- benzinga.com Dyne Therapeutics Q4 EPS $(0.76) Beats $(0.79) Estimate Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.79) by 3.18 percent. This is a 13.64 percent increase over losses of…
benzinga.com Sarepta CEO To Jump Ship After 'Tumultuous' Year Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.- benzinga.com JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $16 JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers the price target from $17 to $16.
- benzinga.com Dyne Therapeutics Announces MHLW In Japan Grants Orphan Drug Designation For Zeleciment Basivarsen For Treatment Of Myotonic Muscular Dystrophy Type 1 - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial -- Expect to complete enrollment in…
- benzinga.com 'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
- benzinga.com Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $36 Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $38 to $36.
- benzinga.com Stifel Maintains Buy on Dyne Therapeutics, Raises Price Target to $39 Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $36 to $39.
benzinga.com Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday - benzinga.com Oppenheimer Upgrades Dyne Therapeutics to Outperform, Raises Price Target to $40 Oppenheimer analyst Andreas Argyrides upgrades Dyne Therapeutics (NASDAQ:DYN) from Perform to Outperform and raises the price target from $11 to $40.